Guangdong Ruijieman Biomedical Technology

Guangdong Ruijieman Biomedical Technology is a biotechnology company based in Guangzhou, China, specializing in the development of innovative cell therapies. The company focuses on creating next-generation off-the-shelf universal CAR-T and CAR-NK cell products to treat solid tumors and autoimmune diseases. By leveraging advanced gene-editing and cell-engineering platforms, Ruijieman aims to address the high costs and manufacturing complexities associated with traditional autologous cell therapies. Their research pipeline includes candidates targeting Glypican-3 and Mesothelin for indications such as liver and pancreatic cancers. The firm operates a state-of-the-art R&D and manufacturing facility to support its clinical development goals.